4//SEC Filing
Decheng Capital China Life Sciences USD Fund III, L.P. 4
Accession 0001626199-21-000118
CIK 0001626199other
Filed
Sep 20, 8:00 PM ET
Accepted
Sep 21, 6:39 PM ET
Size
7.0 KB
Accession
0001626199-21-000118
Insider Transaction Report
Form 4
Transactions
- Purchase
Common Stock
2021-09-17$9.40/sh+1,542,553$14,499,998→ 4,708,288 total
Footnotes (1)
- [F1]The reportable securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
Documents
Issuer
ALPINE IMMUNE SCIENCES, INC.
CIK 0001626199
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001736814
Filing Metadata
- Form type
- 4
- Filed
- Sep 20, 8:00 PM ET
- Accepted
- Sep 21, 6:39 PM ET
- Size
- 7.0 KB